Palatin Technologies, symbolized as (PALI, Financial), has joined forces with Kingswood Capital Partners and Ladenburg Thalmann as the principal book-running managers. This collaboration is aimed at enhancing investment strategies and ensuring robust financial management. Investors seeking to make informed decisions may find the partnership valuable in navigating market challenges effectively.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Palisade Bio Inc (PALI, Financial) is $10.67 with a high estimate of $16.00 and a low estimate of $2.00. The average target implies an upside of 1,221.77% from the current price of $0.81. More detailed estimate data can be found on the Palisade Bio Inc (PALI) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Palisade Bio Inc's (PALI, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
